Karthik Koduru, MD
Hematology & Oncology · Quincy, ILNPI 1720241565
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Lilly USA, LLC at 56.9% of the total. Reporting peaked in 2019 at $30,485 and has fallen 99.9% since, to $23 in 2025.
Across 202 payments — averaging $204.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$24K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Pfizer$3K
- Merck$246
- Novartis$196
- AstraZeneca$184
- plus $2K from 28 others
Across 11 payments — averaging $7787.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$86K
What the payments were for
- Consulting fees$11,66528%
- Speaking & faculty fees$21,30051%
- Travel & lodging$5,18413%
- Food & beverage$3,1088%
- Education$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 40 | $23,535 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $12,160 |
| Pfizer | 11 | $3,487 |
| Merck | 17 | $246 |
| Novartis | 15 | $196 |
| AstraZeneca(2 entities) | 13 | $184 |
| Amgen | 5 | $181 |
| E.r. Squibb & Sons, L.L.C. | 17 | $178 |
| Johnson & Johnson(2 entities) | 13 | $171 |
| Sanofi | 9 | $137 |
| Bristol Myers Squibb | 6 | $127 |
| Genentech USA, Inc. | 7 | $103 |
| Comsort, Inc | 1 | $100 |
| Eisai Inc. | 4 | $74 |
| Rigel Pharmaceuticals, Inc. | 4 | $60 |
| Clovis Oncology, Inc. | 4 | $54 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Foundation Medicine, Inc. | 1 | $44 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| Boehringer Ingelheim | 2 | $31 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $27 |
| Array Biopharma Inc | 2 | $26 |
| Taiho Oncology, Inc. | 2 | $25 |
| GSK | 1 | $23 |
| Tesaro, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| EMD Serono, Inc. | 1 | $12 |
| Incyte Corporation | 1 | $12 |
| Verastem, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,398 in reported general payments places this provider in the 85th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Quincy
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.